Relapse of acute lymphoblastic leukemia in the inferior rectus muscle of the eye
β Scribed by Andrea S. Hinkle; Patricia A. Dinndorf; Dorothy I. Bulas; Sudesh Kapur
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 474 KB
- Volume
- 73
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Background. Extramedullary involvement of acute lymphoblastic leukemia (ALL) in sites outside the central nervous system (CNS) or testes is rare and may signal a refractory form of leukemia.
Methods. The authors describe a child with ALL who experienced a relapse involving the inferior rectus muscle of the eye. This patient had been treated with a bone marrow transplant for previous bone marrow and ovarian relapse.
Results. The patient had a pre-B ALL with a t(1;19) chromosomal translocation and previously had experienced relapse during therapy. At the time of the muscle relapse, she had pancreatomegaly consistent with leukemic infiltration but no CNS or bone marrow disease.
Conclusions. Relapse of ALL in unusual sites may indicate disease that is particularly difficult to eradicate. Factors in addition to age and leukocyte count at diagnosis determine risk. Additional research is needed to define these factors and develop more effective therapy.
π SIMILAR VOLUMES
## Abstract The standard dose of clofarabine is 52 mg/m^2^ for pediatrics and 40 mg/m^2^ in adults. Clofarabine dosed at 52 mg/m^2^ was used in adult patients with refractory ALL to maximize response before alloβHSCT. All patients had a significant response to therapy. Published pharmacokinetic ana
## Abstract The clinical outlook for adults with acute lymphoblastic leukemia (ALL) has Improved with the use of intensive chemotherapy. Complete remissions (CR) are achieved in 80% of adults but the majority relapse on maintenance chemotherapy and a few exhibit primary resistance to induction ther
Six hundred thirty-four children with acute lymphoblastic leukemia (ALL) were randomized to receive sanctuary therapy consisting of either cranial irradiation (CRT) plus intrathecal (IT) methotrexate (MTX) or three courses of intermediate-dose methotrexate (IDM) plus intrathecal methotrexate. Two hu